

Corrigendum

Nature Reviews Drug Discovery 9, 955 (December 2010) | doi:10.1038/nrd3326

The importance of new companies for drug discovery: origins of a decade of new drugs

Robert Kneller

[*Nature Reviews Drug Discovery* 9, 867–883 \(2010\)](#)

In figure 7, the second column in panels a and b should have been labelled 'NDA/BLA applicant'. In the legend for figure 7, and in the article text related to this figure on p879, the subset of the drugs analysed in panel a are those with peak year sales above US\$500 million, rather than mean peak year sales.

[top](#)

[Previous article](#)

[Next article](#)

Nature Reviews Drug Discovery

ISSN 1474-1776

EISSN 1474-1784

[About NPG](#)

[Contact NPG](#)

[Accessibility statement](#)

[Help](#)

[Privacy policy](#)

[Use of cookies](#)

[Legal notice](#)

[Terms](#)

[Naturejobs](#)

[Nature Asia](#)

[Nature Education](#)

[RSS web feeds](#)

Search:

[go](#)

© 2013 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER